Fourth medical device approval following Korea, the U.S., and Vietnam—accelerating global market expansion

AITRICS (CEO Kwang joon Kim), a company specializing in artificial intelligence(AI) technology announced on May 21 that it has received medical device approval from Hong Kong’s Medical Device Division (MDD) for its patient deterioration prediction AI solution, AITRICS-VC (VitalCare).

VitalCare is a medical AI solution that analyzes EMR (electronic medical record) data in real time to predict patient deterioration at an early stage. In general wards, it forecasts the risk of major adverse events—such as death, cardiac arrest, or ICU transfer—within 6 hours, the risk of sepsis within 4 hours, and the risk of cardiac arrest within 24 hours. In the ICU, it predicts the risk of death within 6 hours.

According to Hong Kong’s Health Bureau, total healthcare expenditure in the region reached approximately HKD 284 billion from 2022 to 2023, accounting for 10% of its GDP. With an aging population and a shortage of hospital beds, Hong Kong is experiencing growing demand for smart hospital infrastructure and digital healthcare transformation—positioning it as a strategic hub for medical companies expanding into Asia.

In this context, VitalCare is expected to support faster clinical decision-making, enhance patient safety, and improve hospital operational efficiency. Building on this approval, AITRICS plans to lead medical innovation in the Hong Kong market and accelerate its expansion across Asia.

Kwang joon Kim, CEO of AITRICS, stated, "Our clinical experience in Korea has laid the foundation for gradual market entry into regions with diverse regulatory environments, including the U.S., Vietnam, and now Hong Kong." “This approval demonstrates both the global competitiveness and reliability of VitalCare, proving that it can be applied across various healthcare systems. We will continue to develop solutions that deliver real-world clinical value and meet the universal needs of healthcare providers worldwide.”